格列苯脲及二甲双胍对糖尿病住院患者有效性及安全性分析

目的探讨降糖药格列苯脲与二甲双胍对2型糖尿病住院患者的有效性和安全性。方法将2型糖尿病患者180例随机分为格列苯脲组和二甲双胍组各90例，观察治疗3月后两组患者空腹血糖（FPG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbAlc）、血压、血脂水平及BMI指数的变化情况。结果治疗后两组患者上述各项指标均一定程度下降，组间差异无统计学意义；格列苯脲组HbA1c下降程度高于二甲双胍组，差异有统计学意义；二甲双胍组低血糖事件发生率低于格列苯脲组，差异有统计学意义。结论格列苯脲与二甲双胍均具有良好的降糖作用，各具优势，可依据不同目的指导患者用药。

The efficacy and safety analysis of glibenclamide and metformin in the hospitalized patients with type 2 diabetes

Objective To explore the clinical application of glibenclamide and metformin on their efficacy and safety in hospitalized patients with type 2 diabetes. Methods 180 cases with type 2 diabetes were randomly divided into glibenclamide the phenylurea group and metformin group, each group has 90 cases. After 3 months of treatment, the FPG, 2hPG, HbAlc, blood pressure, blood lipid levels and BMI index were evaluated. Results After treatment, the indicators of this study were all decreased to some extent, but, there was no significant difference between the two groups; The HbA1c contents in glibenclamide group were decreased significantly that higher than the metformin group, whereas the hypoglycemia event rate in metformin group was significantly lower than that in the glibenclamide group. Conclusion Both glibenclamide and metformin have good hypoglycemic effect but they have their own advantages, and clinical guidance can depend on the purpose of the patient＇s medication.